Micafungin Accord (Micafungin)

Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, blocking the synthesis of an essential cell‑wall component. This weakens the fungal cell wall, leading to cell lysis and death while sparing human cells.

The prescribed dose of Micafungin Accord is determined by the treating physician based on the specific infection, patient weight, renal and hepatic function, and clinical guidelines. No standard dosing is provided here.

Safety data for micafungin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis. Echinocandins generally have a favorable safety profile and are effective against many Candida species, including those resistant to azoles, but they are administered intravenously.

Micafungin Accord should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Micafungin Accord is given by intravenous infusion. The infusion rate and duration are set by the prescribing clinician, typically over a period of 30‑60 minutes, and the medication is administered in a clinical setting with appropriate monitoring.

Serious risks include severe allergic reactions such as anaphylaxis, significant liver injury that may present with jaundice, and marked hypotension during infusion. Prompt medical attention is required if any of these events occur.

Patients with a known hypersensitivity to micafungin or any component of the formulation should avoid its use. Caution is also advised for individuals with severe hepatic impairment, and the drug should only be used under specialist supervision in pediatric patients.